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country [l]. Alternatively, this apparent concentration 
of cases in Spain might be due to a high index of 
suspicion for the infection and its associated com- 
plications in a country that has a very high prevalence 
of C. burnetii infection [10-13]. 
We suggest that subclinical rhabdomyolysis may be 
more common than suspected in t h i s  infection, and 
that determination of muscular enzymes should be 
routinely performed in patients with acute Q fever. In 
addition, we believe that the possibility of C .  burnetii 
infection should be considered in the differential 
diagnosis of the febrile patient who presents with 
rhabdomyolysis, regardless of the presence or not of 
pulmonary infiltrates. 
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Quality control limits for antimicrobial susceptibility 
tests of cefpirome 
Clin Microbiol Infect 1999; 5: 771-773 
Cefpirome is a broad-spectrum cephalosporin [I ,2] that 
has been available for use in many countries for the past 
decade. The National Committee for Clinical Labora- 
tory Standards (NCCLS) selects interpretive criteria 
and quality control guidelines for susceptibility tests of 
antimicrobial agents that are marketed in the USA. 
Because US regulatory agencies have not yet con- 
sidered cefpirome for sale in the USA, the NCCLS 
has not been asked to include cefpirome in its tables. 
In November 1997, we performed a 10-laboratory 
collaborative study to define quality control limits for 
disk &sion and broth microdilution tests performed 
according to the current NCCLS methods. These 
studies include tests of Streptococcus pneumoniae ATCC 
49619, Haernophilus infuenzae ATCC 49247, Escherickia 
cofi ATCC 25922, Pseudomoms aetuginosa ATCC 27853, 
Staphylococcus aureus ATCC 25923 and Stapkylococcus 
aureus ATCC 29213. The result of this exercise is 
briefly described here for those who may want to test 
cefpirome by NCCLS methods. 
Commercially prepared 30-pg cefpirome disks 
(BDMS lot 707629 and Oxoid lot 46141) were 
evaluated in parallel. There were no differences in zone 
diameters produced by the two lots of disks, so the data 
were combined for analysis. Six different lots of 
Mueller-Hinton agar h m  four different manufacturers 
were included in the study design. The agar was pre- 
pared as Haemophilus Test Medium (HTM) [3] when 
testing H. inauenzae, and 5% defibrinated sheep blood 
was added to the Mueller-Hinton agars when testing 
Streptococcus pneumoniae. For broth microdilution tests, 
cefpirome was serially diluted in each of five lots of 
cation-adjusted Mueller-Hinton broth f?om three 
different manufacturers. The broth media were pre- 
pared as HTM [4] for testing the H. injuenzae strain or 
supplemented with 2-3% lysed horse blood for testing 
the pneumococcus. Cefotaxime was the control anti- 
biotic: for any day that a cefotaxime result was outside 
of established limits, a l l  cefpirome MIC or zone size 
data for that day were excluded h m  the analysis, even 
though the excluded data were well within the pro- 
posed limits for cefpirome. 
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Table 1 Distribution of cefpirome MICs h m  replicate broth microdilution tests using five Herent lots of cation adjusted 
Muellex-Hinton broth 
~~ ~~ 
Number of times each MIC was mrted'  bv 10 laboratories 
Pseudomonac StcrphyloaKacc StreptoUMarc 
Echerichia wli mginosa a u m  P n c U ~  H. inpumxclc 
MIC ATCC 25922 ATCC 27853 ATCC 29213 ATCC 4%19 ATCC 49247 
(msn) (489 MICS)~ (495 MICS)~ (500 MICS)~ (469 MICs)b (490 MICs)b 
7 8 
1 4.0 99 
2 2.0 342 2 
47 325 10 
170 350 
1 .o 
0.5 
125 0.25 _----- 
0.12 28 12 2 
0.06 347 435 1 
20 0.03 
0.016 1 2 
------ 
------ 
------ 
------ 
------ 2 __---_ ------ 
------ 113 __--_- 
'Broken lines delineate MICs within the proposed control limit. 
bFive hundred MICs were generated for each control strain but some were excluded because MICs of the control 
outside established quality control limits. The number of duable cef@rome MICs is indicated in pventheses for each control stnin. 
(cdotaxime) were 
Table 2 Distribution of zone diameters around 30-pg cefpirome disks 
Number of times each zone of inhibition was reported' by 10 laboratories 
~~ ~ 
Echetichia Pseudomonac Staphylocomrc smp- Hmnnophilur 
ATCC 25922 ATCC 27853 ATCC 25923 ATCC 49619 ATCC 49247 
(396 zones)b (396 zones)b (399 zones)b (379 zones)b (392 zones)b 
wli mginosa a u m  pneumoniac *= 
21 
22 
23 
24 
.25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
1 
1 
4 
18 
43 
65 
103 
68 
63 
23 
8 
1 
1 
------ 
____-_  
2 
33 
95 
111 
74 
30 
5 
I 
------ 
31 
72 
67 
52 
68 
59 
16 
'Broken lines delineate zones within the proposed quality control limits. 
bOf the 400 test results for each control strain, the number in parentheses deugnates the number of duable zone measurement, afta 
excludmg data from days when the cefotaxime zones were outside of established limits. 
The 10 participating laboratories and the director of Rochester Medical Center, Rochester, Ny; J. 
or supervisor of each were: M. Bauman, St Vincent's Hinder, UCLA Medical Center, Los Angela, Ca; S. 
Hospital, Portland, Or; S. Brown, The Clinical Jenkins, Carolinas Medical Center, Charlotte, NC; G. 
Microbiology Institute, WilsonviUe, Or; D. Goldman, O v e d ,  University of New Mexico Medical Center, 
Childrens Hospital, Boston, Ma; D. Hardy, University Albuquerque, NM, M. M e r ,  University of Iowa, 
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Iowa City, Ia; R. Rennie, University of Alberta 
Hospital, Alberta, Canada; and J. Washington, The 
Cleveland Clinic, Cleveland, Oh. 
Broth microdilution and disk &sion suscepti- 
bility tests were performed exactly as outlined by the 
NCCLS [3,4]. The appropriate control s t r a i n s  were 
tested by each participant on 10 separate days. This 
exercise generated 500 MICs of cefpirome and 100 
MICs of the control drug, cefotaxime. Table 1 shows 
the number of MICs that were available for analysis. For 
technical reasons, one participant failed to report two 
MIC values; other data were excluded because the 
MICs of cefotaxime were outside the expected range. 
For disk &ion tests, 400 ce@irome zone dia- 
meters and 200 cefotaxime zones were recorded. 
Cefotaxime disk tests with Streptococcus pneumoniae 
ATCC 49619 were particularly problematic because 
the zones tended to be larger than anticipated. This is 
being further evaluated, and changes in the quality 
control h t s  are now being considered. In the interim, 
21 of 400 cefpirome zone diameters were excluded for 
Table 1 &plays the overall distribution of cefpirome 
MICs with each of five control strains. The broken lines 
encompass tests that are within the proposed control 
limits for each strain. The MIC limits include the 
mode f one two-fold concentration, except for Staphylo- 
coccus aureus ATCC 29213, which includes a four- 
dilution range because of marked skewing of the data 
toward values below the mode. For the same reason, 
four dilution ranges could have been applied to tests of 
this analysis. 
Table 3 Quality control limits for antimicrobial 
susceptibility test of cefpirome 
3O-pg Cefpkome disk Cefpkome 
Control strain 
Eschnichia Cali 
ATCC 25922 
Pseudomom aenrginosa 
ATCC 27853 
Staphylococcus aureus 
ATCC 25923 
Staphylococnrs aureus 
ATCC 29213 
Streptou~cuc pneumoniae 
ATCC 49619 
Hmophiluc influenrae 
ATCC 49247 
zone ckameter (mm) MIC (mg/L) 
30-36 0.03-0.12 
24-3 1 1.04.0 
25-31 NA 
NA 0.25-2.0 
32-38 0.03-0.12 
28-36 0.25-1.0 
the Escherichia coli and H. inauenzae strains, but we 
elected to use a three-dilution range until additional 
information becomes available. Microdilution tests of 
Enterococnrs faecalis ATCC 29212 were also evaluated, 
but the results were not reproducible enough to provide 
useful quality control limits (data not shown). 
Table 2 describes the distribution of zone dia- 
meters generated by this exercise with five different 
control strains. A 7-9-mm range of zones is proposed 
for each control strain.  In each case, at least 95% of all 
the data fell within the proposed ranges. In the past, 
there have been technical problems in manufacturing 
cefpirome disks, but those problems seem to have been 
resolved, since we no longer see lot-to-lot variability 
or differences between manufacturers. However, it is 
prudent for the user to evaluate each new lot of disks 
by testing appropriate control strains before the disks 
are used on patient isolates. The proposed zone size 
limits should be useful for judgmg the acceptability of 
each new lot of disks. 
In summary, we propose the quality control limits 
shown in Table 3. 
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